NASDAQ
1.12USD
-0.03 (-2.61%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
50.5M
P/E
—
EPS
—
Beta
0.99
52W range
0.701-1.45
Day range
1.10–1.14
Open
1.14
Prev close
1.15
Volume
382.7K
Avg volume
287.1K
Dividend
0.00
IPO
2021-08-26
https://www.marketbeat.com/instant-alerts/renovorx-q2-earnings-call-highlights-2026-08-12/ · 8/13/2026+0.80
https://www.globenewswire.com/news-release/2026/02/27/3246506/0/en/RenovoRx-Advancing-RenovoCath-Adoption-at-U-S-Cancer-Centers-Strengthening-Clinical-and-Commercial-Momentum.html · 2/27/2026+0.90
https://seekingalpha.com/article/4851718-renovorx-inc-rnxt-presents-at-iaccess-alpha-virtual-best-ideas-winter-investment-conference · 12/9/2025+0.20
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
